Skip to main content

Advertisement

SpringerLink
Log in

My personal highlights of ESMO 2019 regarding urogenital cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The field of uro-oncology has become more and more important in the past 3 years. ESMO 2019 once again had more highlights in this growing field of medical oncology. The 2019 ESMO annual meeting was an outstanding conference, especially in uro-oncology. Trials with potential for changing the standard of care and novel therapy approaches were presented in bladder cancer and renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grande E, Galsky M, Arranz Arija JA, et al. IMvigor130: efficacy and safety from a phase 3 study of Atezolizumab as Monotherapy or combined with platinum-based chemotherapy vs placebo + PBC in previously untreated locally advanced or metastatic Urothelial carcinoma. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz394.047.

    Article  Google Scholar 

  2. Hoimes CJ, et al. EV-103: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma—initial results. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz249.

    Article  Google Scholar 

  3. Tagawa, et al. TROPHY-U-01: initial results of a phase 2 open-label study of sacituzumab givotecan in patients with metastatic urothelial cancer after failure of platinum-based regimens or immunotherapy. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz394.049.

    Article  Google Scholar 

  4. Van der Heijden MS, et al. Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO). Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz249.003.

    Article  PubMed  Google Scholar 

  5. Grimm MO, et al. A tailored Immunotherapy approach with nivolumab in advanced renal cell carcinoma in the TITAN-RCC trial. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz394.051.

    Article  Google Scholar 

  6. Jonasch E, et al. A first-in-human phase 1/2 trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC. Ann Oncol. 2019; https://doi.org/10.1093/annonc/mdz249.010.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Montleartstraße 37, 1160, Vienna, Austria

    Dora Niedersüß-Beke

Authors
  1. Dora Niedersüß-Beke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dora Niedersüß-Beke.

Ethics declarations

Conflict of interest

D. Niedersüß-Beke declares that she has no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niedersüß-Beke, D. My personal highlights of ESMO 2019 regarding urogenital cancer. memo 13, 157–158 (2020). https://doi.org/10.1007/s12254-020-00605-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-020-00605-0

Keywords

Search

Navigation